Evidence map›Paper›PMID 33036295›Full record

ReviewJournal of fungi (Basel, Switzerland)2020

Isavuconazole-Animal Data and Clinical Data.

Livio Pagano, Chiara Cattaneo, Martina Quattrone, Margherita Oberti, Maria Mazzitelli, Enrico Maria Trecarichi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Methods for Antifungal Susceptibility Testing of theJournal of fungi (Basel, Switzerland) · 2023
    Review
  5. Pulmonary aspergillosis: diagnosis and treatment.European respiratory review : an official journal of the European Respiratory Society · 2022
    Article
  6. New Antifungal Agents with Azole Moieties.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Livio PaganoDipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A. Gemelli IRCCS, 00168 Roma, Italy.
Chiara CattaneoDivisione di Ematologia, ASST-Spedali Civili di Brescia, 25123 Brescia, Italy.
Martina QuattroneSezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Margherita ObertiDivisione di Ematologia, ASST-Spedali Civili di Brescia, 25123 Brescia, Italy.
Maria MazzitelliDepartment of Medical and Surgical Sciences, University of "Magna Graecia"-"Mater Domini" Teaching Hospital, 88100 Catanzaro, Italy.
Enrico Maria TrecarichiDepartment of Medical and Surgical Sciences, University of "Magna Graecia"-"Mater Domini" Teaching Hospital, 88100 Catanzaro, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of invasive fungal infections has deeply evolved in the last years with the inclusion of new antifungals, mainly new azoles (i.e., posaconazole, isavuconazole), to the therapeutic armamentarium. This review focuses on the role of isavuconazole for treating the most important invasive fungal infections both in animals and humans (hematological and non-hematological patients).

Indexed as

antifungal prophylaxisantifungal treatmentIsavuconazole

Identifiers

PMID33036295
PMCPMC7712195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.